ANVS 8-K: Press release attached for second-quarter 2025 results

Rhea-AI Filing Summary

Annovis Bio, Inc. furnished a Current Report on Form 8-K stating that on August 12, 2025 the company issued a press release announcing its financial results for the second quarter ended June 30, 2025 and providing a corporate update. The filing indicates the press release is included as Exhibit 99.1 and also includes the Cover Page Interactive Data File as Exhibit 104. The registrant is identified as an emerging growth company and has elected not to use the extended transition period for new or revised accounting standards.

The 8-K text itself does not present the numerical results or additional operational details; those items are contained in the referenced press release furnished as an exhibit.

Insights

Financial Analyst

Routine disclosure furnishing a press release; no financial figures appear in the 8-K text, so material impact is unclear from this filing alone.

The Form 8-K notifies investors that a press release with the company’s second-quarter 2025 financial results and a corporate update was issued and furnished as Exhibit 99.1. Because the filing does not reproduce the financial statements or key metrics, this document by itself provides limited actionable data for valuation or performance analysis. Investors and analysts must review the attached press release for revenues, earnings, cash position, guidance, or other metrics to assess material impact.

Corporate Governance Expert

Standard Section 2.02 disclosure; filing indicates timely public release via Exhibit 99.1 and notes emerging growth company status.

The 8-K reflects a procedural furnishing of a press release rather than a governance change or transaction. It confirms the company’s status as an emerging growth company and its election not to use the extended transition period for new accounting standards, which are governance-disclosure items of record. No executive departures, related-party transactions, or material governance actions are disclosed in this filing.

false 0001477845 0001477845 2025-08-12 2025-08-12 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of report (Date of earliest event reported): August 12, 2025

ANNOVIS BIO, INC.

(Exact Name of Registrant as Specified in Charter) 

Delaware	001-39202	26-2540421
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

101 Lindenwood Drive, Suite 225
Malvern, PA 19355

(Address of Principal Executive Offices, and Zip Code)

(484) 875-3192

Registrant’s Telephone Number, Including Area Code

                       Not Applicable                       

(Former Name or Former Address, if Changed Since Last Report) 

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.0001 per share	ANVS	New York Stock Exchange

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨ Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company x

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. x

Item 2.02 Results of Operations and Financial Condition.

On August 12, 2025, Annovis Bio, Inc. issued a press release announcing its financial results for the second quarter ended June 30, 2025 and providing a corporate update. A copy of the press release is furnished herewith as Exhibit 99.1.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.		Description
99.1		Press Release Dated August 12, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	ANNOVIS BIO, INC.
Date: August 12, 2025	By:	/s/ Maria Maccecchini
		Name: Maria Maccecchini
		Title: President and Chief Executive Officer

FAQ

What did Annovis Bio (ANVS) report in this 8-K?

The 8-K furnishes a press release dated August 12, 2025 that announces the company’s financial results for the second quarter ended June 30, 2025 and provides a corporate update; the press release is attached as Exhibit 99.1.

Does the Form 8-K include the company’s Q2 2025 financial figures?

No. The 8-K states a press release containing the second-quarter results was issued and is furnished as Exhibit 99.1, but the body of this Form 8-K does not present the numeric financial results.

Is Annovis Bio considered an emerging growth company in this filing?

Yes. The filing indicates Annovis Bio is an emerging growth company and that it has elected not to use the extended transition period for complying with new or revised accounting standards.

What exhibits were filed with this 8-K?

Exhibit 99.1: Press Release dated August 12, 2025; Exhibit 104: Cover Page Interactive Data File (Inline XBRL).

Who signed the 8-K for Annovis Bio (ANVS)?

Maria Maccecchini, President and Chief Executive Officer, signed the Form 8-K on behalf of the registrant.